Boddu Srikanth, Brylka Douglas, Dutruel Silvina P, Spincemaille Pascal, Prince Martin R
Department of Radiology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY, 10065.
Clin Imaging. 2016 Sep-Oct;40(5):979-86. doi: 10.1016/j.clinimag.2016.05.004. Epub 2016 May 24.
Does quantitative analysis of the gadoxetate hepatocyte phase homogeneity, measuring percent standard deviation of hepatocyte phase (SDHP) and liver-to-kidney enhancement ratio (LiKER) detect early hepatic fibrosis?
Retrospective review of gadoxetate liver MRI plus biopsy-proven fibrosis within 6 months included 31 reversible hepatic fibrosis, 33 irreversible hepatic fibrosis, and 15 donors. Parenchymal and vascular SDHP and LiKER were measured on the 20-min hepatocyte phase using region of interest.
Parenchymal SDHP, vascular SDHP and LiKER measurements differentiate early hepatic fibrosis from controls (P<.01).
Quantitative analysis of gadoxetate hepatocyte phase homogeneity using SDHP and LiKER is a promising imaging biomarker for diagnosis of early liver fibrosis.
通过对钆塞酸二钠肝细胞期均匀性进行定量分析，测量肝细胞期标准差百分比（SDHP）和肝肾强化率（LiKER），能否检测出早期肝纤维化？
回顾性分析6个月内接受钆塞酸二钠肝脏MRI检查且经活检证实有纤维化的患者，包括31例可逆性肝纤维化患者、33例不可逆性肝纤维化患者和15例供体。在20分钟肝细胞期使用感兴趣区测量实质和血管的SDHP以及LiKER。
实质SDHP、血管SDHP和LiKER测量值可将早期肝纤维化与对照组区分开来（P<0.01）。
使用SDHP和LiKER对钆塞酸二钠肝细胞期均匀性进行定量分析，是一种有前景的用于诊断早期肝纤维化的成像生物标志物。
